NEWS > INNOVATION

Geniebiome collaborates with CUHK on clinical trial to study the impact of a microbiome immunity formula SIM02 in the reduction of vaccine-related adverse reactions and improvement of COVID-19 vaccine efficacy.

MAR 2021

Study aims to evaluate in elderlies and patients with type 2 diabetes, the impact of G-NiiB Immunity Pro (SIM02) in reduction of vaccine-related adverse reactions and improvement of COVID-19 vaccine efficacy